Supplementary Table 1. Cases of HBV reactivation in patients treated with anti-TNF agents
Reference / Study type / Number of patients / Number of cases of HBV reactivation (HBsAg/anti-HBc antibodies)
Overall / HBsAg, antiviral prophylaxis / HBsAg, no antiviral prophylaxis / Anti-HBc antibodies, antiviral prophylaxis / Anti-HBc antibodies, no antiviral prophylaxis
Anelli et al (2005)1 / Case report / 1 / NS / NS / 0 / 0 / 0/0
Benucci et al (2008)2 / Case report / 1 / 1 / 0 / 0 / 0 / 1/0
Cansu et al (2008)3 / Case report / 2 / 0 / 2 / 0 / 0 / 1/0
Caporali et al (2010)4 / Prospective / 72 / 5 / 0 / 0 / 67 / 0/0
Carroll et al (2008)5 / Case report / 1 / 1 / 0 / 0 / 0 / 1/0
Charpin et al (2009)6 / Retrospective / 23 / NS / NS / 0 / 21 / 0/0
Chung et al (2009)7 / Retrospective / 8 / 0 / 8 / 0 / 0 / 1/0
Colbert et al (2007)8 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Conde-Taboada et al (2008)9 / Case report / 1 / 1 / 0 / 0 / 0 / 0/0
Esteve et al (2004)10 / Prospective / 6 / 1 / 2 / 0 / 3 / 2/0
Fotiadou et al (2010)11 / Retrospective / 7 / 7 / 0 / 0 / 0 / 1/0
Garcia-Sanchez et al (2004)12 / Case report / 1 / 1 / 0 / 0 / 0 / 0/0
Garcia-Vidal et al (2009)13 / Retrospective / 1 / 0 / 1 / 0 / 0 / 1/0
Kaur et al (2008)14 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Kuroda et al (2010)15 / Case report / 1 / 1 / 0 / 0 / 0 / 0/0
Kuwabara et al (2010)16 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Li et al (2009)17 / Retrospective / 3 / 1 / 2 / 0 / 0 / 1/0
Loras et al (2010)18 / Retrospective / 8 / 3 / 4 / 0 / 1 / 3/1
Madonia et al (2007)19 / Case report / 1 / 0 / 0 / 0 / 1 / 0/1
Matsumoto et al (2010)20 / Case report / 1 / 0 / 0 / 0 / 1 / 0/1
Michel et al (2003)21 / Case report / 1 / 1 / 0 / 0 / 0 / 0/0
Millonig et al (2006)22 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Montiel et al (2008)23 / Case report / 1 / 0 / 0 / 0 / 1 / 0/1
Ojiro et al (2008)24 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Oniankitan et al (2004)25 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Ostuni et al (2003)26 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Raftery et al (2007)27 / Case report / 2 / 0 / 0 / 0 / 2 / 0/0
Robinson et al (2009)28 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Roux et al (2006)29 / Case report / 3 / 3 / 0 / 0 / 0 / 1/0
Sakellariou et al (2007)30 / Case report / 2 / 0 / 2 / 0 / 0 / 1/0
Stine et al (2010)31 / Retrospective / 5 / NS / NS / 0 / 0 / 5/0
Suwannalai et al (2009)32 / Retrospective / 1 / NS / NS / 0 / 0 / 0/0
Ueno et al (2005)33 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Urata et al (2010)34 / Retrospective / 52 / 0 / 0 / 0 / 52 / 0/5
Vassilopoulos et al (2010)35 / Prospective / 33 / 14 / 0 / 0 / 19 / 1/0
Verhelst et al (2010)36 / Case report / 1 / 0 / 1 / 0 / 0 / 1/0
Wendling et al (2005)37 / Case report / 4 / 2 / 2 / 0 / 0 / 2/0
Zingarelli et al (2009)38 / Case report / 3 / 3 / 0 / 0 / 0 / 1/0

References

  1. Anelli MG, Torres DD, Manno C, Scioscia C, Iannone F, Covelli M, Schena FP, Lapadula G. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab.Arthritis Rheum. 2005; 52 (8):2519-20.
  2. Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B.J Clin Rheumatol. 2008; 14(4):245-6.
  3. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.J Rheumatol. 2008; 35(3):421-4.
  4. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.Arthritis Care Res (Hoboken). 2010; 62(6):749-54.
  5. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.Semin Arthritis Rheum. 2008; 38(3):208-17.
  6. Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gérolami R. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.Arthritis Res Ther. 2009; 11(6):R179.
  7. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.J Rheumatol. 2009; 36(11):2416-20.
  8. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease.Inflamm Bowel Dis. 2007; 13(11):1453-4.
  9. Conde-Taboada A, Muñoz JP, Muñoz LC, López-Bran E. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol. 2009; 60(6):1077-80.
  10. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.Gut. 2004; 53(9):1363-5.
  11. Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumour necrosis factor-alpha agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol. 2010 Jun 17.
  12. García-Sánchez M, Gómez-Camacho F, Poyato-González A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection.Inflamm Bowel Dis. 2004; 10(5):701-2.
  13. Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, Esteve M, Rodríguez-Carballeira M, Lacasa JM, Salvador G, Garau J. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention.Eur J Clin Microbiol Infect Dis. 2009; 28(4):331-7.
  14. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports.Clin Rheumatol. 2008; 27(8):1069-71.
  15. Kuroda T, Wada Y, Kobayashi D, Sato H, Murakami S, Nakano M, Narita I. Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatol Int. 2010 Jan 9.
  16. Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis.Clin Rheumatol. 2010 Apr 9.
  17. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.Clin Rheumatol. 2009; 28(7):787-91.
  18. Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M; for the REPENTINA study; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.Gut. 2010 Jun 24.
  19. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007; 13(4):508-9.
  20. Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection.Liver Int. 2010 Mar 22.
  21. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.J Rheumatol. 2003l; 30(7):1624-5.
  22. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006; 12(6):974-6.
  23. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient.Liver Int. 2008; 28(5):718-20.
  24. Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab.J Gastroenterol. 2008; 43(5):397-401.
  25. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, Claudepierre P. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004; 31(1):107-9.
  26. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.Ann Rheum Dis. 2003; 62(7):686-7.
  27. Raftery G, Griffiths B, Kay L, Kane D. Chronic viral hepatitis and TNF-alpha blockade. Rheumatology (Oxford). 2007; 46(8):1381-82.
  28. Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford). 2009; 48(4):448-50.
  29. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.Rheumatology (Oxford). 2006; 45(10):1294-7.
  30. Sakellariou GT, Chatzigiannis I. Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection.Clin Rheumatol. 2007; 26(6):950-2.
  31. Stine JG, Khokhar OS, Charalambopoulos J, Shanmugam VK, Lewis JH. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.Arthritis Care Res (Hoboken). 2010; 62(5):704-11.
  32. Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Int J Rheum Dis. 2009; 12(2):118-24.
  33. Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, Kitadai Y, Yoshihara M, Sumii M, Chayama K. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.Dig Dis Sci. 2005; 50(1):163-6.
  34. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients.Mod Rheumatol. 2010 Jul 29.
  35. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.Ann Rheum Dis. 2010; 69(7):1352-5.
  36. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol. 2010; 22(4):494-9.
  37. Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, Toussirot E, Miguet JP, Herbein G, Di Martino V. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy.Ann Rheum Dis. 2005; 64(5):788-9.
  38. Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.J Rheumatol. 2009; 36(6):1188-94.

1